Biotech unter Cash

Zahlen für Q1/23

• keine Umsätze
  
• Verlust 14,3 Mio. $
  
• Cash 62 Mio. $
  
• MK 19 Mio. $
  

- cash runway into the second half of 2024

- SZN-043 Phase 1a with safety data expected by the end of 2023

- SZN-1326 Phase 1a with safety data expected by the end of 2023

https://investors.surrozen.com/news-releases/...financial-results-and

Mit Cash für ca. 4 Quartalen könnten sich die beiden Katalysatoren in Q4 noch gut mitnehmen lassen.

Zahlen für Q2/23

• kein Umsatz
  
• Verlust 9,4 Mio. $
  
• Cash 53 Mio. $
  
• MK 17 Mio. $
  

-SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers continues to enroll with safety data expected by the end of 2023

-SZN-1326 Phase 1a clinical trial in healthy volunteers continues to enroll with safety data expected by the end of 2023

-Corporate prioritization efforts expected to provide cash runway extension into 2025

https://investors.surrozen.com/news-releases/...023-financial-results